Committed, tireless, and persistent.

We are committed to the discovery, development, and commercialization of a transformational generation of targeted therapies for women’s cancers.

Our team spent more than a decade conducting research, and has a deep insight into, endocrine-driven cancers. OP-1250 was the result of that persistence–the first compound designed to realize the Olema vision.

Our Team leadership board of directors
leadership
board of directors
leadership
Sean P. Bohen, M.D., Ph.D. President and CEO
cross
Cyrus Harmon, Ph.D. Chief Technology Officer
cross
Pamela M. Klein, M.D. Chief Medical Officer
cross
Peter Kushner, Ph.D. Chief Scientific Officer
cross
Shane Kovacs Chief Operating and Financial Officer
cross
David C. Myles, Ph.D. Chief Development Officer
cross
Kinney Horn Chief Business Officer
cross
John B. Moriarty Jr., J.D. Executive Vice President and Chief Legal Officer
cross
Leslie Hodges Gallagher, Ph.D. Senior Vice President, Discovery Biology
cross
Sean P. Bohen, M.D., Ph.D. President and CEO
cross
Ian Clark Chairman of the Board
cross
Cindy Butitta Member
cross
Sandra J. Horning, M.D., FACP, FASCO Member
cross
Yi Larson, MBA Member
cross
Andy Rappaport Member
cross
Gorjan Hrustanovic, Ph.D. Member
cross
Graham Walmsley, M.D., Ph.D. Member
cross
Cyrus Harmon, Ph.D. Chief Technology Officer
cross
Julie Dexter Vice President and Head of People
cross
Demiana Faltaos, PharmD, Ph.D Vice President, Head of Clinical Pharmacology
cross
David Kulp, PhD Vice President, Research Informatics
cross
Kristin Lanzi Vice President, Information Technology
cross
Ellen Ashley Vice President of Clinical Operations, Olema Oncology
cross
Eva Stroynowski Vice President, Communications and Investor Relations
cross
Meghna Chowdary Vice President of Competitive and Strategic Assessments
cross
Our Science

We have a clear-eyed recognition of the limitations of current therapies and strategies, but have no intention of limiting what comes next.
Learn More
Our Pipeline

Olema has completed discovery and preclinical studies of OP-1250 required to file an IND and has begun clinical phase research. We anticipate exploring the potential applicability of OP-1250 in a range of metastatic breast cancers, as well as estrogen-driven gynecologic cancers.
Learn More
Press Releases

Here are the latest press releases from Olema.

For further information, visit Investors & Media.

Here are the latest press releases from Olema.

For further information, visit Investors & Media.